# Correction: Nomination Committee Appointed for the 2027 Annual General Meeting of Sprint Bioscience

In the previous press release, the representative for Mats Westinius was omitted. The corrected press release follows below; there are no other changes.

**Sprint Bioscience AB (publ) today announce the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM). In accordance with the established principles for the appointment of the Nomination Committee, it shall consist of the Chair of the Board and three representatives of the company's three largest shareholders.**

The primary task of the Nomination Committee is to submit proposals regarding the election of the Chair of the Board and other Board members, Board remuneration, and the election and remuneration of auditors. In accordance with the established principles, the Nomination Committee shall comprise representatives appointed by the three largest shareholders—based on their shareholding in the company as of the end of September 2026—along with the Chair of the Board (who shall convene the committee).

Accordingly, the following members have been appointed:

- Andreas Lindenhierta, representing First Venture AB
- Jan Lundström, representing Ivar Nordqvist
- Håkan Roos, representing Mats Westinius
- Björn Sjöstrand, Chair of the Board of Sprint Bioscience

The Nomination Committee represents approximately 32.3 percent of the total number of outstanding shares and votes.

The Nomination Committee's proposals will be presented in the Notice to the Annual General Meeting 2027 and on the company's website, www.sprintbioscience.com. Shareholders wishing to provide input or submit proposals to the Nomination Committee may do so via email to valberedning@sprintbioscience.com or by mail to Sprint Bioscience, Attn: Nomination Committee, Novum, 141 57 Huddinge, Sweden.

The Annual General Meeting of Sprint Bioscience will be held on May 12, 2027, at the company's premises in Flemingsberg, Huddinge. Shareholders wishing to have a matter addressed at the Annual General Meeting may submit their proposal to the Chairman of the Board via email at valberedning@sprintbioscience.com or by mail to Sprint Bioscience AB, Attn: Annual General Meeting Matters, Novum, 141 57 HUDDINGE. To ensure inclusion in the notice of the meeting and the agenda for the Annual General Meeting, proposals must be received by the company no later than March 24, 2027—seven weeks prior to the Annual General Meeting.

**For further information, kindly contact:**

Johan Emilsson, CEO, Sprint Bioscience
Phone: +46 (8) 411 44 55
Email: johan.emilsson@sprintbioscience.com

**About Sprint Bioscience AB (publ)**

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

**Attachments**

Nomination Committee Appointed for the 2027 Annual General Meeting of Sprint Bioscience